Neovacs SA Release: 2015 Financial Calendar
Paris, January 26, 2015 – NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for
the treatment of autoimmune diseases, annonced today its financial reporting calendar for 2015.
Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change.
• 2014 Full-Year results February 27, 2015
• Shareholders’ AGM April 8, 2015
• 2015 Half-Year results September 4, 2015
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNa-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. For more information on Neovacs, visit www.neovacs.fr
Contacts
Neovacs
Nathalie Trépo
+33 (0)1 53 10 93 00
ntrepo@neovacs.com
Investor Relations – Financial Communications Germany – MC Services
Raimund Gabriel
+49-89-210228-30
raimund.gabriel@mc-services.eu
Press – U.S. Inquiries – The Ruth Group
Melanie Sollid-Penton
1.646.536.7023
msollid@theruthgroup.com
Help employers find you! Check out all the jobs and post your resume.
Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change.
• 2014 Full-Year results February 27, 2015
• Shareholders’ AGM April 8, 2015
• 2015 Half-Year results September 4, 2015
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNa-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. For more information on Neovacs, visit www.neovacs.fr
Contacts
Neovacs
Nathalie Trépo
+33 (0)1 53 10 93 00
ntrepo@neovacs.com
Investor Relations – Financial Communications Germany – MC Services
Raimund Gabriel
+49-89-210228-30
raimund.gabriel@mc-services.eu
Press – U.S. Inquiries – The Ruth Group
Melanie Sollid-Penton
1.646.536.7023
msollid@theruthgroup.com
Help employers find you! Check out all the jobs and post your resume.